BridgeBio Pharma Inc.
Maricel Apuli (Chief Accounting Officer) sells BBIO shares
About this filing
BridgeBio Pharma Inc. (BBIO) filed Form 4 (insider transaction) with the SEC on Nov 3, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Maricel Apuli · Chief Accounting Officer
Rule 10b5-1 plan · adopted Sep 8, 2025
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | S · open-market saleFootnotes F1 | −2,000 | $72.85 | $145,700.00 | 120,687 | Direct |
Footnotes
- F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.
More BBIO filings
- SC 13G/A
Filed Nov 12, 2026
- 10-Q
Filed Oct 29, 2026
- 8-K
Filed Oct 29, 2026
- SC 13G
Filed Oct 27, 2026
- 8-K
Filed Oct 13, 2026
- 4
Filed Sep 21, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.